Olsen RW, Sieghart W. GABAA receptors: subtypes provide diversity of function and pharmacology. Neuropharmacology. 2009;56:141–8.
Hevers W, Lüddens H. The diversity of GABAA receptors. Pharmacological and electrophysiological properties of GABAA channel subtypes. Mol. Neurobiol. 1998;18:35–86.
Rudolph U, Crestani F, Benke D, Brünig I, Benson JA, Fritschy JM, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature. 1999;401:796–800.
McKernan RM, Rosahl TW, Reynolds DS, Sur C, Wafford KA, Atack JR, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat Neurosci. 2000;3:587–92.
Collinson N, Kuenzi FM, Jarolimek W, Maubach KA, Cothliff R, Sur C, et al. Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor. J Neurosci Off J Soc Neurosci. 2002;22:5572–80.
Guidelines for epidemiologic studies on epilepsy. Commission on Epidemiology and Prognosis, International League Against Epilepsy. Epilepsia. 1993.34: 592–6.
Kapur J, Macdonald RL. Rapid Seizure-Induced Reduction of Benzodiazepine and Zn2+ Sensitivity of Hippocampal Dentate Granule Cell GABAA Receptors. J Neurosci. 1997;17:7532–40.
Naylor DE, Liu H, Wasterlain CG. Trafficking of GABAA Receptors, Loss of Inhibition, and a Mechanism for Pharmacoresistance in Status Epilepticus. J Neurosci. 2005;25:7724–33.
Rossetti AO, Lowenstein DH. Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol. 2011;10:922–30.
Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain. 2011;134:2802–18. Review of available therapies in the treatment of status epilepticus beyond first and second line treatments.
Shorvon S, Ferlisi M. The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain. 2012;135:2314–28. Outcomes of the different therapies for super-refractory status epilepticus.
Alldredge BK, Gelb AM, Isaacs SM, Corry MD, Allen F, Ulrich S, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med. 2001;345:631–7.
Silbergleit R, Durkalski V, Lowenstein D, Conwit R, Pancioli A, Palesch Y, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012;366:591–600. Silbergleit: large-scale trial that showed equivalence between IM midazolam and IV lorazepam in the treatment of prehospital status epilepticus. IM midazolam should be considered as the first-line treatment in ambulatory settings due to the difficulties of gaining IV access, which may compromise the time to treatment.
Knudsen FU. Rectal administration of diazepam in solution in the acute treatment of convulsions in infants and children. Arch Dis Child. 1979;54:855–7.
Dreifuss FE, Rosman NP, Cloyd JC, Pellock JM, Kuzniecky RI, Lo WD, et al. A comparison of rectal diazepam gel and placebo for acute repetitive seizures. N Engl J Med. 1998;338:1869–75.
Scott RC, Besag FM, Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet. 1999;353:623–6.
Mpimbaza A, Ndeezi G, Staedke S, Rosenthal PJ, Byarugaba J. Comparison of buccal midazolam with rectal diazepam in the treatment of prolonged seizures in ugandan children: a randomized clinical trial. Pediatrics. 2008;121:e58–64.
Nakken KO, Lossius MI. Buccal midazolam or rectal diazepam for treatment of residential adult patients with serial seizures or status epilepticus. Acta Neurol Scand. 2011;124:99–103. A comparison of buccal midazolam to rectal diazepam among adult residential patients with intractable seizures. Buccal midazolam was preferred by both patients and caregivers and had similar efficacy.
Scheepers M, Scheepers B, Clarke M, Comish S, Ibitoye M. Is intranasal midazolam an effective rescue medication in adolescents and adults with severe epilepsy? Seizure. 2000;9:417–22.
Bancke LL, Dworak HA, Rodvold KA, Halvorsen MB, Gidal BE. Pharmacokinetics, pharmacodynamics, and safety of USL261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers. Epilepsia. 2015. n/a – n/a.
Henney III HR, Sperling MR, Rabinowicz AL, Bream G, Carrazana EJ. Assessment of pharmacokinetics and tolerability of intranasal diazepam relative to rectal gel in healthy adults. Epilepsy Res. 2014;108:1204–11. A comparison of an intranasal diazepam formulation to rectal diazepam for tolerability and safety in healthy adults. Similar results were achieved.
Agarwal SK, Kriel RL, Brundage RC, Ivaturi VD, Cloyd JC. A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers. Epilepsy Res. 2013;105:362–7.
Leppik IE, Patel SI. Intramuscular and rectal therapies of acute seizures. Epilepsy Behav. 2015;49. A review of the intramuscular and rectal therapies for acute seizures. IM midazolam and rectal diazepam remain as the two best alternatives to IV lorazepam at this time.
Jensen HS, Nichol K, Lee D, Ebert B. Clobazam and its active metabolite N-desmethylclobazam display significantly greater affinities for α2- versus α1-GABA(A)-receptor complexes. PLoS One. 2014;9:e88456.
Shimizu H, Kawasaki J, Yuasa S, Tarao Y, Kumagai S, Kanemoto K. Use of clobazam for the treatment of refractory complex partial seizures. Seizure. 2003;12:282–6.
Ng Y-T, Conry J, Paolicchi J, Kernitsky L, Mitchell W, Drummond R, et al. Long-term safety and efficacy of clobazam for Lennox–Gastaut syndrome: interim results of an open-label extension study. Epilepsy Behav. 2012;25:687–94.
Conry JA, Ng Y-T, Kernitsky L, Mitchell WG, Veidemanis R, Drummond R, et al. Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years. Epilepsia. 2014;55:558–67. Long term open label extension trial for clobazam. A large amount of patients had sustained response at stable dose for three years. Several patients remained on the drug up to five years at relatively stable doses and sustained seizure reduction.
Pinder RM, Brogden RN, Speight TM, Avery GS. Clonazepam: a review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs. 1976;12:321–61.
Troupin AS, Friel P, Wilensky AJ, Moretti-Ojemann L, Levy RH, Feigl P. Evaluation of clorazepate (Tranxene®) as an anticonvulsant—a pilot study. Neurology. 1979;29:458.
Trimble MR. On the Use of Tranquillisers in Epilepsy. Epilepsia. 2002;43:25–7.
Tan KR, Rudolph U, Lüscher C. Hooked on benzodiazepines: GABAA receptor subtypes and addiction. Trends Neurosci. 2011;34:188–97.
Barker MJ, Greenwood KM, Jackson M, Crowe SF. Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol. 2004;19:437–54.
Bateson A. Basic Pharmacologic Mechanisms Involved in Benzodiazepine Tolerance and Withdrawal. Curr Pharm Des. 2002;8:5–21.
Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABA(A) receptor modulators? Adv Pharmacol Sci. 2012;2012:416864.
Clobazam in Treatment of Refractory Epilepsy: The Canadian Experience. A Retrospecti. Epilepsia. 1991. 32: 407–16.
Mitchell WG, Conry JA, Crumrine PK, Kriel RL, Cereghino JJ, Groves L, et al. An open-label study of repeated use of diazepam rectal gel (Diastat) for episodes of acute breakthrough seizures and clusters: safety, efficacy, and tolerance. Epilepsia. 1999;40:1610–7.
Tan KR, Brown M, Labouèbe G, Yvon C, Creton C, Fritschy J-M, et al. Neural bases for addictive properties of benzodiazepines. Nature. 2010;463:769–74.
Engin E, Bakhurin KI, Smith KS, Hines RM, Reynolds LM, Tang W, et al. Neural basis of benzodiazepine reward: requirement for α2 containing GABAA receptors in the nucleus accumbens. Neuropsychopharmacology. 2014;39:1805–15.
Reynolds LM, Engin E, Tantillo G, Lau HM, Muschamp JW, Carlezon WA, et al. Differential roles of GABAA receptor subtypes in benzodiazepine-induced enhancement of brain-stimulation reward. Neuropsychopharmacology. 2012;37:2531–40.